Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3BCHECHRM1CHRM2CHRM3CHRM4CHRNA3CHRNA4CHRNB2CHRNB4ESR1ESR2GABRA1GABRB1GABRG2GBA1GHSRHRH1HTR1DHTR2AMAOBOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8UGCGrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.33 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL9474227 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL191753 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL6332969 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL11054858 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL8467361 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL263200 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL4111185 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL29824737 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL263201 | 0.97 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL7804046 | 0.94 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111547705-B | Preparation method of porous carbon electrode material | 中国计量大学 | 2022-03-29 | — | — | CN | claimed |
| CN-111547705-A | Preparation method of porous carbon electrode material | 中国计量大学 | 2020-08-18 | — | — | CN | claimed |
| US-20150374597-A1 | DENTAL BLEACHING COMPOSITION | OSSTEMIMPLANT CO., LTD (KR) | 2015-12-31 | — | — | US | claimed |
| EP-2957276-A1 | DENTAL BLEACHING COMPOSITION | Osstem Implant Co., Ltd. (KR) | 2015-12-23 | — | — | EP | claimed |
| CN-105025871-A | Dental bleaching composition | OSSTEM IMPLANT CO LTD | 2015-11-04 | — | — | CN | claimed |
| CN-101723473-A | Preparation method of multivariate doping spherical alpha-Ni(OH)2 with nanometer secondary structure | UNIV BEIJING CHEMICAL | 2010-06-09 | — | — | CN | claimed |
| JP-58187167-A | — | — | None | — | — | JP | disclosed |
| JP-58187166-A | — | — | None | — | — | JP | disclosed |
| CN-119950500-A | Tobacco pest-reducing and pain-relieving products and methods thereof | 瑞迪美天然有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025058941-A1 | TOBACCO HARM REDUCTION AND PAIN RELIEF PRODUCTS AND METHODS THEREOF | Ready Mix Naturals, LLC (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250082627-A1 | TOBACCO HARM REDUCTION AND PAIN RELIEF PRODUCTS AND METHODS THEREOF | Ready Mix Naturals, LLC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-118146418-A | Raceme resolution method based on selective dissolution and chiral polymer used by same | 西安交通大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-115236156-A | PAN-BSA (PAN-bovine serum albumin) compound modified electrode for chiral recognition of tryptophan enantiomer as well as preparation method and application of PAN-BSA compound modified electrode | 常州大学 | 2022-10-25 | — | — | CN | disclosed |
| US-4329533-A | Shape selective reactions with zeolite catalysts modified with group IA metals | MOBIL OIL CORPORATION (US) | 1982-05-11 | — | — | US | disclosed |
| US-4324681-A | Chiral supports for resolution of racemates | UOP INC. (US) | 1982-04-13 | — | — | US | disclosed |
| US-4322310-A | Chiral supports for resolution of racemates | UOP INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4318819-A | Chiral supports for resolution of racemates | UOP INC. (US) | 1982-03-09 | — | — | US | disclosed |
| US-4318820-A | Chiral supports for resolution of racemates | UOP INC. (US) | 1982-03-09 | — | — | US | disclosed |
| EP-0039536-A1 | Shape selective reactions with zeolite catalysts modified with group 1A metals | MOBIL OIL CORPORATION (US) | 1981-11-11 | — | — | EP | disclosed |
| US-3953504-A | Racemization of optically active tartaric acid | NIPPON PEROXIDE CO., LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082627-A1 | TOBACCO HARM REDUCTION AND PAIN RELIEF PRODUCTS AND METHODS THEREOF | OPRK1, SYMPK, TAS2R9 | TSHR 306/4885LMNA 4012/4885CYP3A4 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.